Debiopharm is to build a new Innovation building dedicated to research and development at its Valais site in Martigny. The Lausanne-based biopharmaceutical group will invest CHF 30 million in the project…
Debiopharm invests over 30 million francs in innovation in Martigny Read More »
From dynamite to pharmaceuticals, Valsynthèse, the ‘fine chemistry’ business unit of the Société Suisse des Explosifs, celebrates four decades of steering innovative chemical solutions in Valais.
Valsynthèse, 40 years of innovation in the canton of Valais Read More »
BioArk is on a roll! The Monthey-based technology site, which celebrates its 20th anniversary this year, inaugurated its third building on Friday.
BioArk’s third building in Monthey has just been inaugurated and is already almost full! Read More »
The pharmaceutical and biotechnology group Lonza has confirmed the extension of a long-term collaboration with a major global biopharmaceutical partner. The agreement will quadruple current bioconjugation capacity at the Ibex facilities in Visp. The new suites are expected to be operational in 2026 and will generate approximately 180 jobs, according to Lonza.
Lonza plan to create 180 jobs in Visp by 2026 Read More »
The Institute of Life Technologies of the School of Engineering of the HES-SO Valais-Wallis has sealed…
The Institute of Life Technologies of the School of Engineering of the HES-SO Valais-Wallis has sealed…
Fighting cancer: HES-SO Valais-Wallis and Debiopharm sign partnership agreement Read More »
Two Swiss jewels in the crown of pharmaceutical subcontracting rank 1st and 6th in the world ranking published by Genetic Engineering & Biotechnology News. Proof of a booming sector in our canton.
Siegfried and Lonza in the world’s top 10 CDMOs! Read More »
GaDia SA, a Valais-based start-up specializing in the development of diagnostic tests, and HES-SO Valais-Wallis are to collaborate on the development of a new-generation rapid test for the detection of fungal infections such as Invasive Pulmonary Aspergillosis (IPA). This research project is supported by Innosuisse, the Swiss innovation promotion agency, to the tune of CHF 350,000.
A test to detect deadly fungal infections is being developed in Valais Read More »
Swiss company ten23 health has just announced an increase in capacity for the manufacture of sterile…
Swiss CDMO ten23 health increases its sterile production in Visp by 50% ! Read More »
Ten23 health, a company based in Basel and on the BioArk in Visp, announces the launch of “quality…
New services and additional jobs in Visp for Ten23 health Read More »
